Skip to content
OpenCapital
Get started

Boston Scientific BSX Neuromodulation — Net Sales

Other product segments

Interventional Cardiology & Vascular Therapies
$4.64B—
Electrophysiology
$905M+24.0%
Endoscopy
$736M+9.4%
Urology
$646M+2.1%
Cardiac Rhythm Management
$578M0.0%
Watchman
$506M+19.1%
Interventional Oncology & Embolization
$214M—

Similar metrics at other companies

Medtronic logo
MDTUNITED STATES — Net Sales
$4.87B+7.1%
Biogen logo
BIIBSpinal Muscular Atrophy — Product revenues
$448.2M+4.0%
ResMed logo
RMDDevices — Net revenue by segment
$1.47B+8.8%
Neurocrine Biosciences logo
NBIXNet product sales — Total revenues
$811M+43.9%
Biogen logo
BIIBMS Product Revenues — Total Revenue
$957.5M+0.5%
United Therapeutics logo
UTHRRemodulin — Total revenues
$126.6M-8.4%

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.4%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$67.32B-37.5%
P/E18.9×-34.3×
P/S3.3×-2.9×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's neuromodulation — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's neuromodulation — net sales?
Boston Scientific (BSX) reported neuromodulation — net sales of $318M in Q1 2026.
How has Boston Scientific's neuromodulation — net sales changed year-over-year?
Boston Scientific's neuromodulation — net sales increased by 17.3% year-over-year, from $271M to $318M.
What is the long-term trend for Boston Scientific's neuromodulation — net sales?
Over 4 years (2021 to 2025), Boston Scientific's neuromodulation — net sales has grown at a 7.2% compound annual growth rate (CAGR), from $909M to $1.2B.
What does neuromodulation — net sales mean?
Total revenue generated from the sale of medical devices designed to treat neurological conditions through electrical stimulation.
How do you interpret neuromodulation — net sales?
An increase indicates growing market share or higher demand for the company's neuro-technology solutions, while a decrease may signal increased competition or market saturation in the neuromodulation space.
How does neuromodulation — net sales compare across companies?
Comparable to revenue reported by medical device peers specializing in neuro-stimulation, such as Medtronic or Abbott, within their respective neuromodulation or pain management business units.